Wire · opportunities
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
Eli Lilly's investigational drug retatrutide achieved up to 20.8% average weight loss and lowered HbA1C by up to 1.6% over 80 weeks in adults with type 2 diabetes and obesity in the phase 3 TRIUMPH-2 trial. The drug also improved other metabolic markers and showed significant efficacy particularly in participants with a BMI of 35 or higher.
This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it between 30 Sep 2026 and 1 Oct 2026.
◆ ◆ The Wire takeaway
You face a new standard for treating type 2 diabetes with obesity as retatrutide offers weight loss and glucose control in one therapy, demanding a rethink of your product mix and competitive positioning now.
◆ Coverage
2 sources · first reported 30 Sep 2026 · latest 1 Oct 2026
◆ Related on Wire
◆ Topics